Literature DB >> 17003233

Effects of glucose-dependent insulinotropic peptide on osteoclast function.

Qing Zhong1, Takashi Itokawa, Supriya Sridhar, Ke-Hong Ding, Ding Xie, Baolin Kang, Wendy B Bollag, Roni J Bollag, Mark Hamrick, Karl Insogna, Carlos M Isales.   

Abstract

Acute nutrient ingestion leads to a rapid inhibition of bone resorption while effects on makers of bone formation are less marked or absent, suggesting that there is a transient shift toward skeletal accretion in the immediate postprandial period. The cellular bases for these effects are not clear. Glucose-dependent insulinotropic peptide (GIP), a known modulator of glucose-induced insulin secretion, is secreted from intestinal endocrine cells in response to nutrient ingestion. In addition to the effect of GIP on pancreatic beta-cells, GIP receptors are expressed by osteoclastic cells [corrected] in bone, suggesting a role for this incretin hormone in bone formation. To determine whether GIP also plays a role in the anti-resorptive effect of nutrient ingestion, osteoclasts were analyzed for the presence of GIP receptors by PCR, immunohistochemical and immunocytochemical analyses of bone tissue, and freshly isolated mature osteoclasts and osteoclast-like cells cultured in vitro. Osteoclast function was assessed by fetal long bone resorption assay and by use of the Osteologic disc assay. Our results demonstrate that GIP receptor transcripts and protein are present in osteoclasts. In addition, with the use of an in vitro organ culture system and mature osteoclasts, GIP was found to inhibit bone resorption in the organ culture system and the resorptive activity of mature osteoclasts. These data are consistent with the hypothesis that GIP inhibits bone breakdown through a direct effect on osteoclast-resorptive activity and suggest one mechanism for the postprandial reduction in markers of bone breakdown.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17003233     DOI: 10.1152/ajpendo.00364.2006

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  50 in total

1.  Association of DPP-4 activity with BMD, body composition, and incident hip fracture: the Cardiovascular Health Study.

Authors:  L D Carbone; P Bůžková; H A Fink; J A Robbins; M Bethel; C M Isales; W D Hill
Journal:  Osteoporos Int       Date:  2017-02-02       Impact factor: 4.507

Review 2.  Diabetes pharmacotherapy and effects on the musculoskeletal system.

Authors:  Evangelia Kalaitzoglou; John L Fowlkes; Iuliana Popescu; Kathryn M Thrailkill
Journal:  Diabetes Metab Res Rev       Date:  2018-12-20       Impact factor: 4.876

Review 3.  Effects of Incretin-Based Therapies and SGLT2 Inhibitors on Skeletal Health.

Authors:  Andrea Egger; Marius E Kraenzlin; Christian Meier
Journal:  Curr Osteoporos Rep       Date:  2016-12       Impact factor: 5.096

Review 4.  The pathogenic role of the GIP/GIPR axis in human endocrine tumors: emerging clinical mechanisms beyond diabetes.

Authors:  Daniela Regazzo; Mattia Barbot; Carla Scaroni; Nora Albiger; Gianluca Occhi
Journal:  Rev Endocr Metab Disord       Date:  2020-03       Impact factor: 6.514

Review 5.  Bone and mineral metabolism in patients undergoing Roux-en-Y gastric bypass.

Authors:  M P Hage; G El-Hajj Fuleihan
Journal:  Osteoporos Int       Date:  2013-09-06       Impact factor: 4.507

6.  Risk of fractures and diabetes medications: a nationwide cohort study.

Authors:  H J Choi; C Park; Y-K Lee; Y-C Ha; S Jang; C S Shin
Journal:  Osteoporos Int       Date:  2016-04-14       Impact factor: 4.507

Review 7.  The role of incretins in glucose homeostasis and diabetes treatment.

Authors:  Wook Kim; Josephine M Egan
Journal:  Pharmacol Rev       Date:  2008-12-12       Impact factor: 25.468

8.  Reduced amylin levels are associated with low bone mineral density in women with anorexia nervosa.

Authors:  Monica H Wojcik; Erinne Meenaghan; Elizabeth A Lawson; Madhusmita Misra; Anne Klibanski; Karen K Miller
Journal:  Bone       Date:  2009-11-18       Impact factor: 4.398

9.  Glucose-Dependent Insulinotropic Peptide Prevents Serum Deprivation-Induced Apoptosis in Human Bone Marrow-Derived Mesenchymal Stem Cells and Osteoblastic Cells.

Authors:  J L Berlier; I Kharroubi; J Zhang; A Dalla Valle; S Rigutto; M Mathieu; V Gangji; J Rasschaert
Journal:  Stem Cell Rev Rep       Date:  2015-12       Impact factor: 5.739

10.  Impact of glucose-dependent insulinotropic peptide on age-induced bone loss.

Authors:  Ke-Hong Ding; Xing-Ming Shi; Qing Zhong; Baolin Kang; Ding Xie; Wendy B Bollag; Roni J Bollag; William Hill; Walter Washington; Qing-Sheng Mi; Karl Insogna; Norman Chutkan; Mark Hamrick; Carlos M Isales
Journal:  J Bone Miner Res       Date:  2008-04       Impact factor: 6.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.